Shota Yamazaki

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1850809/publications.pdf

Version: 2024-02-01

37 papers	1,423 citations	516710 16 h-index	345221 36 g-index
37 all docs	37 docs citations	37 times ranked	2217 citing authors

#	Article	IF	Citations
1	FDG uptake in PET is associated with the tumor microenvironment in metastatic lymph nodes and prognosis in N2 lung adenocarcinoma. Cancer Science, 2022, , .	3.9	3
2	Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer. Expert Review of Anticancer Therapy, 2022, 22, 169-182.	2.4	7
3	Prognostic impact of count of extratumoral lymphatic permeation in lung adenocarcinoma and its relation to theÂimmune microenvironment. Cancer Science, 2022, 113, 1497-1506.	3.9	3
4	Pathologic method for extracting good prognosis group in tripleâ€negative breast cancer after neoadjuvant chemotherapy. Cancer Science, 2022, 113, 1507-1518.	3.9	6
5	Component with abundant immuneâ€related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Cancer Science, 2022, , .	3.9	3
6	Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer. Pathobiology, 2021, 88, 218-227.	3.8	2
7	Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer, 2021, 153, 1-10.	2.0	43
8	Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses. International Journal of Cancer, 2021, 149, 546-560.	5.1	18
9	Prognostic impact of extranodal extension in patients with pN1â€“N2 lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3699-3707.	2.5	6
10	The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer. Cancer Science, 2021, 112, 2895-2904.	3.9	9
11	Uptake of collagen type I via macropinocytosis cause mTOR activation and anti-cancer drug resistance. Biochemical and Biophysical Research Communications, 2020, 526, 191-198.	2.1	19
12	Secretion of high amounts of hepatocyte growth factor is a characteristic feature of cancerâ€associated fibroblasts with EGFRâ€TKI resistanceâ€promoting phenotype: A study of 18 cases of cancerâ€associated fibroblasts. Pathology International, 2019, 69, 472-480.	1.3	15
13	Prognostic Impact of the Number of Metastatic Lymph Nodes on the Eighth Edition of the TNM Classification of NSCLC. Journal of Thoracic Oncology, 2019, 14, 1408-1418.	1.1	43
14	Interaction between cancer cells and cancer-associated fibroblasts after cisplatin treatment promotes cancer cell regrowth. Human Cell, 2019, 32, 453-464.	2.7	7
15	Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma. Lung Cancer, 2019, 136, 57-64.	2.0	10
16	Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells. Lung Cancer, 2019, 134, 100-107.	2.0	40
17	Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Scientific Reports, 2019, 9, 17145.	3.3	15
18	Spatiotemporal characteristics of fibroblasts-dependent cancer cell invasion. Journal of Cancer Research and Clinical Oncology, 2019, 145, 373-381.	2.5	6

#	Article	IF	Citations
19	Collagen type I induces <scp>EGFR</scp>â€<scp>TKI</scp> resistance in <scp>EGFR</scp>â€mutated cancer cells by <scp>mTOR</scp> activation through Aktâ€independent pathway. Cancer Science, 2018, 109, 2063-2073.	3.9	39
20	CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors. Scientific Reports, 2017, 7, 46662.	3.3	36
21	A novel method to generate single-cell-derived cancer-associated fibroblast clones. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1409-1419.	2.5	12
22	Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2016, 142, 37-46.	2.5	10
23	Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Advanced Drug Delivery Reviews, 2016, 99, 186-196.	13.7	340
24	Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. International Journal of Cancer, 2015, 137, 784-796.	5.1	106
25	Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation. Clinical Cancer Research, 2015, 21, 642-651.	7.0	98
26	Impact of Extratumoral Lymphatic Permeation on Postoperative Survival of Nonâ€“Small-Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2014, 9, 337-344.	1.1	18
27	Identification of intravascular tumor microenvironment features predicting the recurrence of pathological stage <scp>I</scp> lung adenocarcinoma. Cancer Science, 2013, 104, 1262-1269.	3.9	21
28	Identification of Biological Properties of Intralymphatic Tumor Related to the Development of Lymph Node Metastasis in Lung Adenocarcinoma. PLoS ONE, 2013, 8, e83537.	2.5	12
29	Prognostic Impact of Cancer-Associated Stromal Cells in Patients With Stage I Lung Adenocarcinoma. Chest, 2012, 142, 151-158.	0.8	106
30	Morphophenotypic characteristics of intralymphatic cancer and stromal cells susceptible to lymphogenic metastasis. Cancer Science, 2012, 103, 1342-1347.	3.9	10
31	Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification. Chest, 2011, 139, 855-861.	0.8	38
32	Long-term Survival and Risk Factors for Recurrence in Stage I Non-small Cell Lung Cancer Patients With Tumors up to 3 cm in Maximum Dimension. Chest, 2010, 138, 357-362.	0.8	42
33	A Novel Histopathological Evaluation Method Predicting the Outcome of Non-small Cell Lung Cancer Treated by Neoadjuvant Therapy: The Prognostic Importance of the Area of Residual Tumor. Journal of Thoracic Oncology, 2010, 5, 49-55.	1.1	47
34	Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2010, 5, 1507-1515.	1.1	159
35	Vascular Invasion Is a Strong Prognostic Factor After Complete Resection of Node-Negative Non-small Cell Lung Cancer. Chest, 2010, 138, 1411-1417.	0.8	30
36	Area of residual tumor beyond the muscular layer is a useful predictor of outcome in rectal cancer patients who receive preoperative chemoradiotherapy. Pathology International, 2009, 59, 857-862.	1.3	11

#	Article	IF	Citations
37	Evaluation of extratumoral lymphatic permeation in non-small cell lung cancer as a means of predicting outcome. Lung Cancer, 2007, 55, 61-66.	2.0	33